Peter Evan Davis MD

Child Neurology•Boston, MA

Neurodevelopmental Disabilities

Child Neurologist at Boston Children's Hospital

Join to View Full Profile

300 Longwood AveMailstop BCH 3433Boston, MA 02115
Phone+1 617-355-2711
Fax+1 617-730-0288

Summary

Dr. Peter Davis is a Child Neurologist in Boston, MA and is affiliated with Boston Children's Hospital. He received his medical degree from Warren Alpert Medical School of Brown University and has been in practice 7 years. He is experienced in tuberous sclerosis, child neurology, behavioral disorders, neurodevelopmental disabilities, and autism spectrum disorders.

Education & Training

Boston Children’s Hospital/Beth Israel Deaconess Medical Center/Harvard Medical SchoolFellowship, Child Neurology, 2015 - 2017
Boston Children’s Hospital/Beth Israel Deaconess Medical Center/Harvard Medical SchoolResidency, Child Neurology, 2012 - 2015
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pediatrics, 2010 - 2012
The Warren Alpert Medical School of Brown UniversityClass of 2010

Certifications & Licensure

MA State Medical License 2015 - 2026
NH State Medical License 2024 - 2024
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology

Clinical Trials

Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) Start of enrollment: 2013 Jan 01
Completed
Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
ACTIVE_NOT_RECRUITING
Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
COMPLETED
PHASE2
RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome Start of enrollment: 2017 Jun 12
COMPLETED
PHASE1, PHASE2
Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex Start of enrollment: 2017 Apr 12
Terminated
Phase 2
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Start of enrollment: 2021 Oct 13
RECRUITING
PHASE2
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC Start of enrollment: 2022 Mar 03
ACTIVE_NOT_RECRUITING
PHASE2
A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome Start of enrollment: 2022 Dec 16
TERMINATED
PHASE2
Join now to see all

Publications & Presentations

PubMed

3 citations
Abnormality of Early White Matter Development in Tuberous Sclerosis Complex and Autism Spectrum Disorder: Longitudinal Analysis of Diffusion Tensor Imaging Measures.
Siddharth Srivastava, Fanghan Yang, Anna K Prohl, Peter E Davis, Jamie K Capal
Journal of Child Neurology. 2024-05-01
7 citations
Development and Feasibility of the Self-Report Quantified Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders Checklist (TAND-SQ).
Tosca-Marie Heunis, Nola Chambers, Stephanie Vanclooster, Stacey Bissell, Anna W Byars
Pediatric Neurology. 2023-10-01
17 citations
International consensus recommendations for the identification and treatment of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).
Petrus J de Vries, Tosca-Marie Heunis, Stephanie Vanclooster, Nola Chambers, Stacey Bissell
Journal of Neurodevelopmental Disorders. 2023-09-14

Journal Articles

The Spectrum of Movement Disorders in Childhood‐Onset Lysosomal Storage Diseases
Peter E Davis, Clara Hildebrandt, Irina Anselm, Lance H Rodan, Movement Disorders Clinical Practice